health

Novartis CAR-T therapy leads to durable response in lymphoma study

(Reuters) – Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis’ new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday. Swiss drugmaker Novartis’ logo is seen at …

health

Hospital operators in merger talks to form U.S. industry leader: WSJ

NEW YORK (Reuters) – Ascension Health and Providence St. Joseph Health are in talks about a merger between the two Catholic non-profits that would create the largest U.S. hospital chain, the Wall Street Journal reported on Sunday, citing people familiar with the discussions. A deal between St. Louis-based Ascension and …

health

Hospital operators in merger talks to create U.S. industry leader: WSJ

NEW YORK (Reuters) – Ascension Health and Providence St. Joseph Health are in discussions about a merger that would create the largest hospital chain in the United States, the Wall Street Journal reported on Sunday, citing people familiar with the situation. A deal between the two non-profits would give the …

health

France orders international recall of Lactalis baby formula

PARIS (Reuters) – France has ordered banned the sale and ordered a recall of several baby formula milk and baby food products made by French dairy giant Lactalis after the discovery of salmonella bacteria, consumer protection agency DGCCRF said in a statement. Logo of the dairy group Lactalis are seen …

health

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

(Reuters) – More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. The logo of Gilead Sciences Inc is pictured …

health

Roche lymphoma drug drives high remission rate, longer survival: study

(Reuters) – An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment alone, according to data from a mid-stage trial released at a medical meeting on …

health

Drug industry group sues to stop California drug price law

(Reuters) – The trade group representing U.S. drugmakers on Friday said it has a filed a lawsuit to stop California from implementing a law aimed at reining in prescription drug prices. The Pharmaceutical Research and Manufacturers of America (PhRMA), in a statement, said it filed litigation in the U.S. District …

health

U.S. House committee 'may reconsider' WHO cancer agency funds

LONDON (Reuters) – U.S. congressional committee members warned on Friday that Washington’s funding of the World Health Organization’s cancer research agency could be halted unless it is more open about its operations. A logo is pictured on the World Health Organization (WHO) headquarters in Geneva, Switzerland, November 22, 2017. REUTERS/Denis …

health

Lilly's stomach cancer drug meets main goal, but fails to improve survival rate

(Reuters) – Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a gastric cancer treatment met the main goal of preventing the disease from advancing, but failed its secondary target of improving overall survival rates. The company said it would not seek a regulatory …

health

Lilly's Cyramza meets main goal in gastric cancer study

(Reuters) – Eli Lilly & Co said on Friday a late-stage trial testing its drug, Cyramza, as a treatment for a type of gastric cancer met its main goal of preventing the disease from advancing. However the trial failed its secondary goal of improving overall survival of the patients. Lilly …